Entrada Therapeutics Inc (TRDA)
Healthcare
Biotechnology
—
6.80 $
+0.3%
vs. previous close
Closing price · As of: 31. Jul 2026
Who owns Entrada Therapeutics Inc (TRDA)? This page shows the largest institutions and funds, the ownership structure and the latest insider transactions. 50.2% of the shares are freely tradable; institutional investors hold 78.7%.
Ownership Structure
Institutional ownership
Share of the stock held by institutional investors (funds, banks, insurers) according to regulatory filings.
78.7%
Insiders
Share of the stock held by the executives, founders and major shareholders of the company itself.
12.3%
Float
Share of stock freely tradable on the market — not locked up in the hands of founders, insiders, or major shareholders.
50.2%
Short % of float
Shares sold short as a percentage of the freely tradable float — high values signal many bets on falling prices.
7.7%
Shares Outstanding
Total number of shares issued. Price times share count gives market cap.
39Mio.
Largest Shareholders
Institutions
| Name | Stake (%) | Shares | Change (%) | Date |
|---|---|---|---|---|
| Baker Bros Advisors LP | 13.07 | 5,072,730 | +0.0 | 03/31/2026 |
| 5AM Venture Management, LLC | 10.45 | 4,056,379 | +0.0 | 03/31/2026 |
| BlackRock Inc | 6.08 | 2,358,793 | +9.9 | 03/31/2026 |
| TCG Crossover Management, LLC | 5.89 | 2,287,500 | +9.5 | 03/31/2026 |
| Vanguard Group Inc | 4.21 | 1,632,460 | +1.8 | 12/31/2025 |
| Vanguard Capital Management, LLC | 3.24 | 1,256,013 | +0.0 | 03/31/2026 |
| Wellington Management Company LLP | 2.67 | 1,034,782 | -1.0 | 03/31/2026 |
| StepStone Group LLC | 1.96 | 761,277 | +0.0 | 03/31/2026 |
Funds
| Name | Stake (%) | Shares | Change (%) | Date |
|---|---|---|---|---|
| Vanguard Total Stock Mkt Idx Inv | 2.46 | 953,727 | +0.0 | 04/30/2026 |
| iShares Russell 2000 ETF | 1.76 | 682,700 | +0.9 | 05/29/2026 |
Largest reported positions according to regulatory filings; stake as a percentage of shares outstanding, change versus the previous filing. Source: fundamentals data.
Data as of: July 31, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.